De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
BioNTech Toekomstige groei
Future criteriumcontroles 0/6
De winst van BioNTech zal naar verwachting dalen met 5.3% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 7% per jaar. De winst per aandeel zal naar verwachting dalen met 3.2% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -2.9% zijn.
Belangrijke informatie
-4.9%
Groei van de winst
-3.2%
Groei van de winst per aandeel
| Biotechs winstgroei | 28.8% |
| Inkomstengroei | 7.0% |
| Toekomstig rendement op eigen vermogen | -2.9% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 03 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
BioNTech SE (NASDAQ:BNTX) Shares Fly 27% But Investors Aren't Buying For Growth
Sep 13
BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward
Aug 20BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise
Aug 06Improved Revenues Required Before BioNTech SE (NASDAQ:BNTX) Shares Find Their Feet
Jun 16BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical
Jun 13Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year
May 11Analyst Estimates: Here's What Brokers Think Of BioNTech SE (NASDAQ:BNTX) After Its First-Quarter Report
May 08BioNTech Earnings Preview: I Will Stay On The Sidelines
May 03BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Apr 22We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings
Mar 27BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 24BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions
Mar 20BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time
Feb 23BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate
Feb 09Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%
Jan 18Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price
Jan 02BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Dec 11Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook
Oct 22BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet
Sep 11Is BioNTech (NASDAQ:BNTX) A Risky Investment?
Jun 13A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)
May 23BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates
Mar 29These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely
Mar 05A Look At The Fair Value Of BioNTech SE (NASDAQ:BNTX)
Feb 18Bearish: Analysts Just Cut Their BioNTech SE (NASDAQ:BNTX) Revenue and EPS estimates
Feb 02With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case
Jan 26Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 2,723 | -716 | -623 | 516 | 15 |
| 12/31/2025 | 2,697 | -670 | -904 | 470 | 19 |
| 12/31/2024 | 2,682 | -594 | 360 | 2,168 | 19 |
| 6/30/2024 | 2,691 | -504 | 2,352 | 2,972 | N/A |
| 3/31/2024 | 2,730 | 113 | 4,944 | 5,732 | N/A |
| 12/31/2023 | 3,819 | 930 | 4,666 | 5,371 | N/A |
| 9/30/2023 | 6,618 | 2,751 | 4,690 | 5,350 | N/A |
| 6/30/2023 | 9,184 | 4,375 | 8,726 | 9,317 | N/A |
| 3/31/2023 | 12,213 | 6,238 | 8,493 | 8,850 | N/A |
| 12/31/2022 | 17,311 | 9,434 | 13,214 | 13,577 | N/A |
| 9/30/2022 | 18,565 | 10,322 | 12,277 | 12,549 | N/A |
| 6/30/2022 | 21,191 | 11,748 | 9,040 | 9,271 | N/A |
| 3/31/2022 | 23,303 | 12,863 | 5,066 | 5,251 | N/A |
| 12/31/2021 | 18,977 | 10,293 | 736 | 890 | N/A |
| 9/30/2021 | 13,790 | 7,493 | 1,198 | 1,338 | N/A |
| 6/30/2021 | 7,770 | 4,072 | -474 | -355 | N/A |
| 3/31/2021 | 2,503 | 1,197 | -376 | -270 | N/A |
| 12/31/2020 | 482 | 15 | -99 | -13 | N/A |
| 9/30/2020 | 165 | -410 | -382 | -326 | N/A |
| 6/30/2020 | 126 | -230 | -239 | -183 | N/A |
| 3/31/2020 | 110 | -192 | -268 | -222 | N/A |
| 12/31/2019 | 109 | -179 | -270 | -198 | N/A |
| 9/30/2019 | 144 | -122 | -220 | -138 | N/A |
| 6/30/2019 | 136 | -116 | -142 | -75 | N/A |
| 3/31/2019 | 132 | -77 | -136 | -55 | N/A |
| 12/31/2018 | 128 | -48 | -126 | -59 | N/A |
| 12/31/2017 | 62 | -86 | N/A | -53 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat BNTX de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat BNTX de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat BNTX de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van BNTX ( 7% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.7% per jaar).
Hoge groei-inkomsten: De omzet van BNTX ( 7% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Er wordt voorspeld dat BNTX binnen 3 jaar verliesgevend zal zijn.